Rasagiline

  • (R) -N-2 -propynyl -1 - indanamin
  • (R )-N- prop-2- ynyl -2 ,3- dihydro-1H -inden- 1-amine
  • C12H13N ( rasagiline )
  • C12H13N · CH4O3S ( rasagiline · methylsulphonate )

N04BD02

Monoamine oxidase inhibitors

Irreversible inhibition of MAO -B

Template: Infobox chemical / molecular formula search available

Rasagiline is a drug for the treatment of Parkinson's disease. In the countries of the European Union, it is approved as a methanesulfonate salt since July 2005, under the trade name Azilect ®.

Rasagiline belongs to the group of selective monoamine oxidase inhibitors ( MAOIs) and is a MAO - B inhibitor, the second generation. It inhibits MAO -B five to ten times stronger than the selegiline previously available from this group.

The short with 0.6-2 hours half-life of rasagiline has no practical significance, since the MAO -B is irreversible blocked. The clinical duration is therefore determined by the rate of biosynthesis of the enzyme in the body.

Rasagiline is approved for early monotherapy of idiopathic Parkinson's disease, with symptomatic efficacy and delay the start of treatment with dopaminergic therapy by controlled studies showed. Also approved rasagiline is for the combination treatment of patients with motor fluctuations.

Trade names

Rasagiline is available under the name Azilect commercially available in Germany, Austria, Switzerland and the EU.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System DrugBank Active ingredient
670110
de